AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03274297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMW PIB patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
Study NCT01852136 — intervention group
Intervention type: DEVICE
Intervention: BD NEXT 31G x 5 mm pen needle
Description: Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
Study NCT01852136 — intervention group
Intervention type: DEVICE
Intervention: BD NEXT 31G x 8mm pen needle
Description: Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
Study NCT01852136 — intervention group
Intervention type: DEVICE
Intervention: BD NEXT 32G x 4mm pen needle
Description: Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
Study NCT02290093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard full-volume PEG
Description: Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
Study NCT02290093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split-dose full-volume PEG
Description: Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
Study NCT02290093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split-dose low-volume PEG
Description: Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
Study NCT01365572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xiene V stent, Endeavor Resolute stent
Description: for each lesion, randomized either Xience V stent or Endeavor Resolute stent
Study NCT00727064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Study NCT00727064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine Extended Release (VEN ER)
Study NCT04073407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1957
Description: Amino acids, food study
Study NCT04073407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04524923 — intervention group
Intervention type: OTHER
Intervention: visual motor integration
Description: investigate the relation between touch screen usage and visual motor integration in preschoolers
Study NCT04524923 — intervention group
Intervention type: OTHER
Intervention: Quality of life assessment
Description: investigate the relation between touch screen usage and Quality of life assessment in preschoolers
Study NCT04524923 — intervention group
Intervention type: OTHER
Intervention: Cognitive Functioning
Description: investigate the relation between touch screen usage and Cognitive Functioning assessment in preschoolers
Study NCT00479232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Study NCT00479232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Study NCT01680172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
Study NCT01680172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of liquid placebo solution taken by mouth
Study NCT02408822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA Balloon dilatation catheter Advance® (Cook® Medical)
Description: 2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
Study NCT02408822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®
Description: 2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
Study NCT02109224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02109224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02109224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02505061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital-based Program
Description: The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team.
Study NCT02505061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Therapy Program
Description: The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase
Study NCT01562691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasopore
Description: Bilateral nasal packing using Nasopore without airway integrated
Study NCT01562691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: airway integrated Nasopore
Description: post nasoseptoplasty with nasal packing using airway integrated Nasopore
Study NCT01562691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: airway-integrated Vaseline gauze
Description: post nasal septoplasty with packing using airway-integrated Vaseline gauze
Study NCT03541642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange
Study NCT03541642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Intervention
Description: General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
Study NCT04455334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error-augmented treadmill training
Description: walk on split-belt treadmill
Study NCT04624243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
Study NCT04624243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone administered QD at a dose of 6 mg via oral capsule.
Study NCT04624243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-8189
Description: MK-8189-matching placebo administered QD via oral tablet.
Study NCT04624243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-8189
Description: MK-8189-matching placebo administered QD via oral tablet.
Study NCT04624243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to risperidone
Description: Risperidone-matching placebo administered QD via oral capsule.
Study NCT02520973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sputum sample
Study NCT02520973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sputum sample
Study NCT01022580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infasurf surfactant (ONY, Inc.)
Description: Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
Study NCT01022580 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
Study NCT02314884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cafusertib Hydrochloride
Study NCT00890162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Study NCT00890162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine
Study NCT00890162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab (Xolair)
Study NCT00890162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT05246748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Caring Theory based Education
Description: The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
Study NCT05246748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: The control group received solely standard education program for one sessions in prenatal period.
Study NCT02073617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Real-time 3-dimensional DynaCT
Description: After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
Study NCT04455334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active control group
Description: walk on tie-belt treadmill
Study NCT04455334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error-augmented concept combined physical therapy group
Description: Error-augmented concept combined physical therapy
Study NCT03807843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V184
Description: Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.
Study NCT03807843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile physiological saline for IM injection
Study NCT01312129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: 500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
Study NCT01312129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule x 3 doses 12 hours apart
Study NCT02534480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NGP 555
Description: Gamma-secretase modulator for the treatment of Alzheimer's disease
Study NCT00884949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~* Weeks 1-12: 0.1 mg/kg/week~* Weeks 13-24: 1.0 mg/kg/week~* Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week.
Study NCT02625740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local exposition of target lesion to high intensity, low-frequency ultrasound
Description: Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
Study NCT04455334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy group
Description: conventional physical therapy
Study NCT04455334 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION
Study NCT02625740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting ballon angioplasty
Description: Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
Study NCT02625740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow occlusion with an angioplasty balloon
Description: Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
Study NCT02625740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Paclitaxel infusion
Description: Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
Study NCT03309163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patient-controlled intravenous analgesia with Tramadol
Study NCT02625740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiographic control
Description: A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
Study NCT02625740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiographic control
Description: A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
Study NCT03600129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Qadratus Lumborum Block
Description: Bilateral, ultrasound - guided Quadratus Lumborum Block
Study NCT03600129 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Qadratus Lumborum Block
Description: Bilateral, ultrasound - guided Quadratus Lumborum Block
Study NCT03600129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 milliliters of 0.375% Ropivacaine
Description: 30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
Study NCT03600129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 30 milliliters of 0.9% NaCl
Description: 30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
Study NCT03309163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: Patient-controlled intravenous analgesia with Hydromorphone
Study NCT03309163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine (Epidural analgesia)
Description: Patient-controlled epidural analgesia with Ropivacaine.
Study NCT01397929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL101553
Description: Intravenous administration
Study NCT04639063 — intervention group
Intervention type: OTHER
Intervention: Microscopic examination using H&E stained slides
Description: Reexamination of the stained slides of the patients from the hospital archive and adding a CD10 stain when required
Study NCT03583346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6495
Description: Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
Study NCT03583346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
Study NCT00000142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
Study NCT00787722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Infusion of participant's own stem cells
Study NCT03233750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training
Description: see description in arm/group descriptions
Study NCT03233750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis Resource Management
Description: During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
Study NCT03642314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self test kit
Description: HIVST receptor will be invited to priority access to PrEP sites
Study NCT02126332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ropivacaine and sufentanil
Description: Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
Study NCT02126332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: acetaminophen, nefopam, tramadol, opidoids
Description: Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
Study NCT01949987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: two hours
Study NCT01949987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one hour
Study NCT03754647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: One tablet of Vitamin C (500 mg) twice daily with SSRIs for 8 weeks
Study NCT03119311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video-oculography
Description: Diagnostic Method for Exotropia Using Video-oculography
Study NCT03119311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: APCT
Description: alternative prism cover test
Study NCT03860753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
Study NCT03860753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill capsules will look same as that of active drug.
Study NCT01620099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extrafine treatment (Clenilexx(R) or Foster(R))
Description: Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
Study NCT01620099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extrafine treatment (Clenilexx(R) or Foster(R))
Description: Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
Study NCT01033942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP
Description: Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
Study NCT01033942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Study NCT01033942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Many Men, Many Voices (3MV)
Description: Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.